Compounds > 4-hydroxylomustine
Page last updated: 2024-12-07

4-hydroxylomustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxylomustine: RN given refers to (trans)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92073
CHEMBL ID1970179
CHEMBL ID2051940
SCHEMBL ID3341308
SCHEMBL ID3341311
MeSH IDM0121377

Synonyms (42)

Synonym
nsc-240025
nsc 239717
trans-4-hydroxy ccnu
nsc240024
nsc239717
nsc-239724
cis-4-oh ccnu
52049-26-0
urea, 1-(2-chloroethyl)-3-(cis-4-hydroxycyclohexyl)-1-nitroso-
cis-4-hydroxy ccnu
nsc 239724
nsc-239717
56239-24-8
nsc-240024
nsc239724
nsc240025
urea, 1-(2-chloroethyl)-3-(trans-4-hydroxycyclohexyl)-1-nitroso-
trans-4-oh ccnu
NCI60_001924
4-hydroxylomustine
trans-4-hydroxy-ccnu
n-(2-chloroethyl)-n'-(trans-4-hydroxycyclohexyl)-n-nitrosourea
1-(2-chloroethyl)-3-(trans-4-hydroxycyclohexyl)-1-nitrosourea
cis-4-oh-ccnu
cis-4-hydroxy-ccnu
urea, n-(2-chloroethyl)-n'-(4-hydroxycyclohexyl)-n-nitroso-, trans-
urea, n-(2-chloroethyl)-n'-(4-hydroxycyclohexyl)-n-nitroso-, cis-
1-(2-chloroethyl)-3-(cis-4-hydroxycyclohexyl)-1-nitrosourea
1-(2-chloroethyl)-3-(4-hydroxycyclohexyl)-1-nitrosourea
CHEMBL1970179
CHEMBL2051940
SCHEMBL3341308
SCHEMBL3341311
1-(2-chloroethyl)-3-(4-hydroxycyclohexyl)-1-nitroso-urea
cis-4-hydroxy-lomustine
DTXSID30879605
1-no-1(2clet)-3(4-oh cyhexyl)urea
DTXSID201177048
n-(2-chloroethyl)-n'-(cis-4-hydroxycyclohexyl)-n-nitrosourea
4-hydroxy-lomustine, cis-
DT68Z5XSS5
urea, n-(2-chloroethyl)-n'-(cis-4-hydroxycyclohexyl)-n-nitroso-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1149520Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as time delay in tumor growth at 45 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1132757Retention time in Wistar rat liver microsomes at 50 ug/ml after 10 mins by HPLC analysis1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
AID1133739Therapeutic index, ratio of LD10 for BDF1 mouse to ED50 for mouse L1210 cells allografted in ip dosed BDF1 mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1149524Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as disease cure administered as single dose1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1133737Toxicity in ip dosed BDF1 mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1149521Antitumor activity against mouse early Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as disease cure administered as single dose on 1 or 2 days post-tumor implantation measured for 80 days post-drug treatment1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149525Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as complete regression of established tumor administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149527Antitumor activity against mouse advanced Lewis lung carcinoma allografted in ip dosed BDF1 mouse assessed as increase in host lifespan administered as single dose on day 6 or 7 post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID23276Partition coefficient (logP)1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID1149483Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 30 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1133740Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1149492Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 45 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149511Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as time delay in tumor growth at 30 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID134226Toxicity against L-1210 leukemia cells in mice after intraperitoneal administration, activity is expressed as LD101980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID125581Tested for 3 log kill of leukemia cells1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID1133738Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Synthesis of analogues of N-(2-chloroethyl)-N'-(trans-4-methylcyclohexyl)-N-nitrosourea for evaluation as anticancer agents.
AID1149466Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 38 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149494Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as time delay in tumor growth at 38 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149523Ratio of ED50 for antitumor activity against mouse L1210 cells allografted in ip dosed mouse to LD10 for mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149486Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as increase in host life span at 26 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID1149514Antitumor activity against mouse early Lewis lung carcinoma allografted in BDF1 mouse assessed as time delay in tumor growth at 26 mg/kg, ip administered as single dose on 1 or 2 days post-tumor implantation1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.
AID139104Partition coefficient (logP)1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
AID139629Tested for toxicity against L-1210 leukemia cells in mice after ip administration, activity is expressed as LD101980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.98 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.8740N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
lomustine
[no description available]		3.4680N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
semustine
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.. semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.		2.6430N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent
ethylnitrosourea
Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.		1.9610N-nitrosoureasalkylating agent;
carcinogenic agent;
genotoxin;
mutagen
1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea
1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea: structure		2.6530
elmustine
elmustine: structure		1.9810
1-(2-chloroethyl)-1-nitrosourea
[no description available]		2.3620
1-(2-fluoroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-fluoroethyl)-3-cyclohexyl-1-nitrosourea: fluoro analog		1.9510
nsc 153174
NSC 153174: RN given refers to (cis)-isomer		2.6430
1,4-dihydropyridine
[no description available]		1.9710
dihydropyridines
Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.		1.9710
2-((3-chloroethyl)-3-nitrosoureido)glucopyranose
[no description available]		2.3620
ConditionIndicatedRelationship StrengthStudiesTrials
Germinoblastoma
[description not available]		01.9510
Experimental Neoplasms
[description not available]		02.3620
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		01.9510
Leukemia L 1210
[description not available]		02.6430
Carcinoma, Anaplastic
[description not available]		01.9510
Cancer of Lung
[description not available]		01.9510
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		01.9510
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9510
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610
Glial Cell Tumors
[description not available]		01.9610
Malignant Melanoma
[description not available]		01.9610
Cancer of Cecum
[description not available]		01.9610
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		01.9610
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9610